Copyright
©The Author(s) 2020.
World J Hepatol. Nov 27, 2020; 12(11): 1076-1088
Published online Nov 27, 2020. doi: 10.4254/wjh.v12.i11.1076
Published online Nov 27, 2020. doi: 10.4254/wjh.v12.i11.1076
NA group (n = 24) | Peg-IFN-NA group (n = 24) | P value | |
Age (yr) | 54 (36-60) | 45 (26-63) | 0.07 |
Male sex, n (%) | 18 (75) | 22 (91) | 0.12 |
IL28B polymorphism, n (%) | 0.25 | ||
CC | 9 (38) | 13 (54) | |
CT/CT | 15 (62) | 11 (46) | |
Origin (ethnicity), n (%) | 0.20 | ||
European | 17 (70) | 12 (50) | |
Asia | 3 (12) | 9 (38) | |
Africa | 2 (8) | 3 (12) | |
AST (IU/mL) | 20 (15-59) | 22 (15-38) | 0.69 |
ALT (IU/mL) | 20 (12-101) | 23 (15-50) | 0.41 |
GGT (IU/mL) | 23 (9-197) | 22 (11-125) | 0.44 |
LSM, n (%) | 0.32 | ||
< 7.2 kPa | 23 (96) | 24 (100) | |
7.2-12 kPa | 1 (4) | 0 (0) | |
NA treatment, n (%) | 0.32 | ||
Tenofovir | 16 (67) | 12 (50) | |
Entecavir | 6 (25) | 9 (38) | |
Others | 2 (8) | 3 (12) | |
NA treatment duration (wk) | 378 (113-763) | 272 (139-495) | 0.06 |
HBV genotype, n (%) | 0.43 | ||
A | 5 (21) | 4 (17) | |
B | 1 (4) | 3 (12) | |
C | 0 (0) | 2 (8) | |
D | 10 (42) | 8 (33) | |
E | 1 (4) | 2 (8) | |
F | 0 (0) | 1 (4) | |
Not available | 7 (29) | 4 (18) | |
Baseline HBcrAg (log 10 U/mL) | 2.7 (< 2-4.9) | 2.3 (< 2-3.7) | 0.18 |
Baseline HBcrAg (log10 U/mL), n (%) | 0.39 | ||
< 2 | 6 (25) | 9 (38) | |
2-2.5 | 4 (17) | 6 (25) | |
2.5-3 | 6 (25) | 3 (12) | |
3-3.5 | 2 (8) | 3 (12) | |
3.5-4 | 3 (13) | 3 (12) | |
> 4 | 3 (13) | 0 (0) | |
Baseline HBsAg (log10 IU/mL) | 3.1 (1.3-4.2) | 3.2 (1.6-4.4) | 0.25 |
Baseline HBsAg (IU/mL), n (%) | 0.22 | ||
> 1000 | 12 (50) | 14 (48) | |
100-1000 | 7 (29) | 9 (38) | |
< 100 | 5 (21) | 1 (4) | |
HBcrAg decline (log10 U/mL) | |||
Δ Week 24 | 0.00 (-1.10-1.21) | 0.00 (-0.71-0.30) | 0.96 |
Δ Week 48 | 0.00 (-1.00-0.30) | 0.00 (-1.31-1.10) | 0.25 |
Δ Week 96 | 0.00 (-1.00-0.10) | 0.00 (-0.71-0.71) | 0.12 |
HBsAg decline (log10 IU/mL) | |||
Δ Week 24 | -0.11 (-0.04-0.00) | -0.26 (-3.8-0.1) | 0.01 |
Δ Week 48 | -0.10 (-1.17-0.04) | -0.40 (-4-0.02) | 0.00 |
Δ Week 96 | -0.12 (-1.39-0.96) | -0.44 (-4-0.01) | 0.00 |
HBsAg Loss; n (%) | 0 (0) | 3 (12.5) | 0.07 |
- Citation: Broquetas T, Garcia-Retortillo M, Micó M, Canillas L, Puigvehí M, Cañete N, Coll S, Viu A, Hernandez JJ, Bessa X, Carrión JA. Hepatitis B surface antigen and hepatitis B core-related antigen kinetics after adding pegylated-interferon to nucleos(t)ids analogues in hepatitis B e antigen-negative patients. World J Hepatol 2020; 12(11): 1076-1088
- URL: https://www.wjgnet.com/1948-5182/full/v12/i11/1076.htm
- DOI: https://dx.doi.org/10.4254/wjh.v12.i11.1076